drugset
drugset / Trial / NCT06326723

Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

NCT06326723 ↗

Phase 1 Completed 32 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical study to assess the PK characteristics and safety and tolerability of single and multiple dose daridorexant in 32 healthy adult Chinese subjects.

Timeline

Start
2023-09-04
Primary completion
2023-12-24
Completion
2024-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 25 mg Oral
Subject Daridorexant Small molecule 50 mg Oral

Indications

No indication recorded.